Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has acquired Apellis Pharmaceuticals, a pharmacy business in Massachusetts, for $1 million. Apellis Pharmaceuticals develops therapies in the healthcare sector, and the pharmacy acquisition supports Biogen acquisitions focused on expanding treatment options. Biogen acquisitions in MA are structured as a merger acquisition, with Aspen Purchaser Sub, Inc. acting as the wholly owned subsidiary offeror. The strategic acquisition is a healthcare M&A tender offer for all outstanding Apellis common shares at $41.00 per share plus a contractual, non-transferable contingent value right up to $4.00 based on specified milestones, with the deal announced and sized under $10M.